

**Joseph J. Tomasek, Esq.**  
**77 North Bridge Street**  
**Somerville, New Jersey 08876**

**(973) 224-1061**

Licensed in New York  
and New Jersey

Of Counsel:  
Mintz & Fraade, P.C.  
488 Madison Avenue  
New York, N.Y. 10022  
(212) 486-2500

**February 28, 2015**

ATTORNEY – CLIENT PRIVILEGED

**VIA-EMAIL ONLY**

OTC Markets Group, Inc.  
2<sup>nd</sup> Floor  
304 Hudson Street  
New York, New York 10013

Re: Herborium Group, Inc.

We have been retained as General Counsel to Herborium Group, Inc., a Nevada Corporation (the "Company"). Our engagement includes (a) entering into an Attorney Letter Agreement with the OTC Markets Group, Inc. (the "OTC") and (b) submitting this Attorney Letter for publication on the OTC Disclosure & News Service in accordance with the requirements set forth in the Attorney Letter Guidelines and Attorney Letter Agreement, signed and submitted by the undersigned to the OTC Markets Group's Issuer Services on February 28, 2015. The OTC may rely on this Attorney Letter in determining whether the Company has made "adequate current information" publicly available within the meaning of Rule 144 (c) (2) of the Securities Act of 1933, as amended (the "Securities Act").

The undersigned Attorney is a resident of the United States of America and is licensed to practice law in the states of New York and New Jersey and this letter covers the jurisdictions of New York and New Jersey as well as the applicable laws of the United States of America. In addition, the undersigned Attorney is permitted to practice before the U.S. Securities and Exchange Commission (the "SEC") and has not been prohibited from practice before the SEC.

In connection with the preparation of this Attorney Letter, I have examined the Herbarium Group, Inc. Consolidated Financial Statements as of and for the fiscal year ended November 30, 2014 (the "Financial Statements"), and its Annual Disclosure Statement for the period ended November 30, 2014 (the "Disclosure Statement") posted by the Company on the OTC Disclosure & News Service on February 27, 2015, and such other Company records, certificates of officers, certificates of public officials, and other instruments and documents and such questions of law as I have considered necessary and appropriate as a basis for the opinions expressed herein

**OTC Markets Group, Inc.**  
**February 28, 2015**  
**Page Two**

(together with the Financial Statements and the Disclosure Document, all information referenced is collectively referred to as the "Information") and all such sources for the Information referenced herein I have deemed reliable.

**The Company maintains a fiscal year end of November 30.**

In rendering this letter, the undersigned Attorney has personally met with management and with all the current Directors of the Company, and has reviewed the Financial Statement and the Disclosure Statement published by the Company through the OTC Disclosure & News Service on February 27, 2015, and personally discussed the Financial Statement and the Disclosure Statement with management and all the Directors of the Company.

Based upon the forgoing, I am of the opinion that: (i) the Information constitutes "adequate current public information" concerning the securities of the Company and that the Information is "publicly available" within the meaning of Rule 144 (c) (2) under the Securities Act as a result of the posting of the Financial Statements and the Disclosure Statement through the OTC Disclosure & News Service on February 27, 2015 (ii) that the Financial Statements and the Disclosure Statement include all of the information that a broker-dealer would be required to obtain from the Company in order to publish a quotation for the securities of the Company under Rule 15c2-11 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"); (iii) the Financial Statements and the Disclosure Document comply as to form with the OTC Market Group's OTC Pink Disclosure Guidelines which are located at the internet at [www.otcmarkets.com](http://www.otcmarkets.com), and; (iv) the Financial Statements and the Disclosure Statement have been posted through the OTC Disclosure & News Service on February 27, 2015.


The financial statements contained in the Disclosure Statement are not audited and were prepared by Dr. Agnes P. Olszewski, Ph.D., MBA. Dr. Olszewski is the Company's President and CEO. Dr. Olszewski has substantial experience in international business and finance and has represented to us that the financial statements were prepared in accordance with U.S. Generally Accepted Accounting Principles.

The transfer agent for the Company is Colonial Stock Transfer Co., Inc., 66 Exchange Place, Salt Lake City, Utah 84111. Colonial Stock Transfer Co., Inc. is registered with the SEC under the Exchange Act. The undersigned personally confirmed the number of outstanding shares set forth in the Disclosure Statement with an officer of Colonial Stock Transfer on February 27, 2015.

To the best knowledge of the undersigned and after diligent inquiry of management and the Directors of the Company, none of the Company, any 5% holder or the undersigned Counsel, is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

**OTC Markets Group, Inc.**  
**February 28, 2015**  
**Page Three**

The OTC Markets Group may rely upon this Attorney Letter and to whom the undersigned grants full and complete permission and rights to publish this Attorney Letter through the OTC Disclosure & News Service for viewing by the public and regulators. This Attorney Letter may not be relied upon by any other person or for any other purpose without the prior written consent of the undersigned.

A handwritten signature in black ink, appearing to read "Joseph J. Tomasek", is written over a horizontal line. The signature is stylized with a large, sweeping initial "J".

**Joseph J. Tomasek, Esq.**